Purpose: Pancreatic carcinoma is highly resistant to therapy. EGFR and HER2 have been reported to be both dysregulated in this cancer. To evaluate the in vivo impact of binding both EGFR and HER2 with two therapeutic humanized monoclonal antibodies (mAbs), we treated human pancreatic carcinoma xenografts, expressing high EGFR and low HER2 levels.
Introduction
The incidence of pancreatic cancer has steadily increased over the past four decades, and its prognosis is still dismal, despite all efforts in early diagnosis and therapy. Even with a complete surgical resection, the five-year survival rate is less than 20% (1) . Conventional therapies associating surgery and radiotherapy often in combination with chemotherapy show modest efficacy in local control and palliation, and no real progress in patient survival (2) (3) (4) . Thus, novel approaches to human pancreatic carcinoma therapy are urgently needed.
Among the numerous biochemical and genetic abnormalities which were found to be associated with this malignancy (3), we were interested by the fact that two receptors of the HER tyrosine kinase family EGFR (ErbB1 or HER1) and HER2 (ErbB2) are expressed in a significant percentage of cases ranging from 45 to 95% for EGFR (5, 6 ) and 43 to 69% for HER2 (7, 8) . The levels of HER2 expression, however, were low in the majority of tumors. Furthermore, the overexpression of EGFR and HER2 receptors is often caused by encoding gene amplification (9) . EGFR and HER2 are known to play an essential role in regulating cell proliferation and differentiation. They have a strong tendency to assemble with other HER receptors into homo-and/or heterodimers upon extracellular growth factor binding, which results in various forms of signal transduction pathways activation, leading to either apoptosis, survival, or cell proliferation (9, 10) .
Mounting evidence suggests that not only receptor overexpression but also communication among HER receptors plays a crucial role in tumor behavior (11, 12) . In particular, binding of receptor-specific ligands to the ectodomain of EGFR often results in the recruitement of HER2, as the preferred heterodimerization partner (13) (14) (15) . As HER2 is the only HER family member that does not bind a known specific ligand, its principal biological function, as a signal transducer, appears to result from its participation in heterodimeric receptor complexes with EGFR or other HER receptors (14) (15) (16) .
The use of mAbs binding with high affinity to these two members of the HER family, EGFR and HER2, thus appears to be rational for the development of new cancer therapy strategies which would have the potential to inhibit the receptor dimerization. Until now, however, each of the two mAbs have been used in cancer therapy individually in conjunction with various chemotherapeutic drugs (17,18) or more recently in association with different drugs having tyrosine kinase receptor inhibition properties (16, 19) . The action of small tyrosine kinase inhibitor molecules, however, cannot be compared with the potential biological activity induced by the binding of a high molecular weight antibody molecule.
The mechanism of anti-tumor activity of individual anti-HER receptor mAbs is not entirely understood. A series of experimental results in mice KO for the Fc receptor strongly suggested that most of the anti-tumor effect was due to the recruitment of effector NK cells by an antibody dependent cell-mediated cytotoxic (ADCC) mechanism (20) . However, the evidence of inhibition of receptor phosphorylation and receptor internalization induced on tumor cells by the anti-HER receptor mAbs argues in favor of an apoptotic or cytostatic signal transduced through the receptor (9, (21) (22) (23) (24) .
Concerning anti-EGFR mAbs, such as cetuximab (Erbitux) or matuzumab (EMD72000), they were shown to compete with the EGFR ligands and inhibit tumor cell proliferation in vitro and in xenograft mouse models. Both mAbs were shown in clinical trials to be well tolerated (18, 25) and active mostly in conjonction with various chemotherapeutic agents, against metastatic colorectal carcinomas (i.e., doxorubicin, adriamycin, taxol, and cisplatin) (18) , leading to approval by the FDA of cetuximab. Interestingly, clinical studies showed that the anti-EGFR mAb had anti-tumor activity even in patients with colorectal carcinomas expressing no detectable amounts of the receptor by immunohistochemistry (26) . Thus, a phase II trial of pancreatic carcinoma treatment with the cetuximab anti-EGFR in combination with gemcitabine appeared justified, but the results of 12.2% partial responses were not very encouraging (6).
For anti-HER2 mAbs, their anti-tumor activity is unlikely to be due to an inhibition of ligand binding since no specific ligand for this receptor has been identified (9, 14) . The therapeutic efficacy of the anti-HER2 mAb, trastuzumab, in breast carcinoma is well demonstrated, but it is strictly limited and only approved for the 30% of tumors overexpressing HER2 (17). Thus, the present day consensus is that anti-HER2 mAb is inefficient in tumors with low HER2 expression, which is the case for most pancreatic carcinoma in the clinic (7, 8) .
Despite this limitation, in view of the known unique biological cooperation and dimerization properties of EGFR and HER2 and the numerous encouraging in vitro results (9-16), we decided to evaluate the anti-tumor effect of the combined injection of two high affinity anti-EGFR and anti-HER2 mAbs, matuzumab and trastuzumab. The two-mAb treatment led to far greater tumor regression and mice survival than injection of each of the mAbs alone, suggesting that the two-mAb treatment could overcome some of the limitations encountered in the treatment with trastuzumab of low HER2 expressing tumors.
Interestingly, the demonstration of therapeutic synergism of the two mAbs was also confirmed on xenografts from the human ovarian xenograft cell line, SK-OV- antibody (Chemicon international, Australia).
Statistical Methods. Survival curves were drawn, and the logrank test was performed to assess differences between groups. All reported P values are twosided. For all statistical tests, differences were considered as significant at the 5% level.
Statistical analyses were performed on an IBM PC-compatible personal computer using the STATA 9.0 software (Stata Corporation, College Station, Texas, USA).
Results

EGFR and HER2 Receptor Cell Surface Expressions. Immunohistochemical analyses on BxPC-3 xenografts showed a high level of EGFR (classified as +++)
but no detectable levels of HER2 receptor expression, as compared with SK-OV-3 xenograft, classified as +++ for HER2 and ++ for EGFR, respectively ( Fig. 1 ).
MiaPaCa-2 xenografts were classified negative for HER2 and ++ for EGFR. In contrast, using the more sensitive flow cytometry technique (27), a moderate expression of HER2 was found on BxPC-3 and MiaPaCa-2 cells as compared with SK-OV-3 cells. The overexpression of EGFR by BxPC-3 cells was confirmed.
MiaPaCa-2 showed a moderate and equal expression of both EGFR and HER2
receptors. SK-OV-3 showed a moderate expression of EGFR and a high expression of HER2 (Fig. 1) .
Anti-tumor Activity of Matuzumab and/or Trastuzumab Against Two
Pancreatic and an Ovarian Carcinoma Xenografts. The therapeutic efficacy of the anti-EGFR and anti-HER2 mAbs alone or in combination was first tested on (Fig. 3A) . This confirms that even with the larger tumors the double specificity of the two mAb was more effective than the absolute mAb doses and that the greater anti-tumor effect was due to a synergistic rather than an additive effect of the two mAbs.
The tumor growth inhibition property of the combined anti-EGFR and anti- Effects of trastuzumab and matuzumab alone or in combination on EGFR and HER2 expression of SK-OV-3 xenograft by immunohistochemical analysis. Tumors were analysed after 2 weeks of Treatments (200 µg per injection)
